Polymorphisms in VEGFA gene affect the antihypertensive responses to enalapril

详细信息    查看全文

• 作者：G. H. Oliveira-Paula ; R. Lacchini ; V. Fontana…
• 关键词：Enalapril ; Haplotypes ; Hypertension ; Polymorphisms ; VEGFA
• 刊名：European Journal of Clinical Pharmacology
• 出版年：2015
• 出版时间：August 2015
• 年：2015
• 卷：71
• 期：8
• 页码：949-957
• 全文大小：542 KB
• 参考文献：1.Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA J Am Med Assoc 289(19):2560-572View Article
  2.von Lueder TG, Krum H (2013) RAAS inhibitors and cardiovascular protection in large scale trials. Cardiovasc Drugs Ther 27(2):171-79View Article
  3.Mentz RJ, Bakris GL, Waeber B, McMurray JJ, Gheorghiade M, Ruilope LM, Maggioni AP, Swedberg K, Pina IL, Fiuzat M, O’Connor CM, Zannad F, Pitt B (2013) The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol 167(5):1677-687PubMed Central PubMed View Article
  4.Ebrahimian TG, Tamarat R, Clergue M, Duriez M, Levy BI, Silvestre JS (2005) Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Arterioscler Thromb Vasc Biol 25(1):65-0PubMed
  5.Ferroni P, Della-Morte D, Palmirotta R, Rundek T, Guadagni F, Roselli M (2012) Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies. Curr Vasc Pharmacol 10(4):479-93PubMed View Article
  6.Li P, Kondo T, Numaguchi Y, Kobayashi K, Aoki M, Inoue N, Okumura K, Murohara T (2008) Role of bradykinin, nitric oxide, and angiotensin II type 2 receptor in imidapril-induced angiogenesis. Hypertension 51(2):252-58PubMed View Article
  7.Silvestre JS, Kamsu-Kom N, Clergue M, Duriez M, Levy BI (2002) Very-low-dose combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide induces an early and sustained increase in neovascularization in rat ischemic legs. J Pharmacol Exp Ther 303(3):1038-043PubMed View Article
  8.Toblli JE, Cao G, DeRosa G, Di Gennaro F, Forcada P (2004) Angiotensin-converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats. Am J Hypertens 17(2):172-80PubMed View Article
  9.Yazawa H, Miyachi M, Furukawa M, Takahashi K, Takatsu M, Tsuboi K, Ohtake M, Murase T, Hattori T, Kato Y, Murohara T, Nagata K (2011) Angiotensin-converting enzyme inhibition promotes coronary angiogenesis in the failing heart of Dahl salt-sensitive hypertensive rats. J Card Fail 17(12):1041-050PubMed View Article
  10.Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669-76PubMed View Article
  11.Eppler SM, Combs DL, Henry TD, Lopez JJ, Ellis SG, Yi JH, Annex BH, McCluskey ER, Zioncheck TF (2002) A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 72(1):20-2PubMed View Article
  12.Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM (2009) Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 54(3):652-58PubMed Central PubMed View Article
  13.Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER (2003) The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107(10):1359-365PubMed View Article
  14.Horowitz JR, Rivard A, van der Zee R, Hariawala M, Sheriff DD, Esakof DD, Chaudhry GM, Symes JF, Isner JM (1997) Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 17(11):2793-800PubMed View Article
  15.Ku DD, Zaleski JK, Liu S, Brock TA (1993) Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 265(2 Pt 2):H586–H592PubMed
  16.Liu MH, Jin HK, Floten HS, Yang Q, Yim AP, Furnary A, Zioncheck TF, Bunting S, He GW (2001) Vascular endothelial growth factor-mediated endothelium-dependent relaxation is blunted in spontaneously hypertensive rats. J Pharmacol Exp Ther 296(2):473-77PubMed
  17.Messadi E, Aloui Z, Belaidi E, Vincent MP, Couture-Lepetit E, Waeckel L, Decorps J, Bouby N, Gasmi A, Karoui H, Ovize M, Alhenc-Gelas F, Richer C (2014) Cardioprotective effect of VEGF and venom VEGF-like protein in acute myocardial ischemia in mice: effect on mitochondrial function. J Cardiovasc Pharmacol 63(3):274-81PubMed View Article
  18.Thijs AM, van Herpen CM, Sweep FC, Geurts-Moespot A, Smits P, van der Graaf WT, Rongen GA (2013) Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans. Hypertension 61(5):1060-065PubMed View Article
  19.Vyzantiadis T, Karagiannis A, Douma S, Harsoulis P, Vyzantiadis A, Zamboulis C (2006) Vascular endothelial growth factor and nitric oxide serum levels in arterial hypertension. Clin Exp Hypertens 28(7):603-09PubMed View Article
  2
• 作者单位：G. H. Oliveira-Paula (1)
  R. Lacchini (2)
  V. Fontana (3)
  P. S. Silva (4)
  C. Biagi (5)
  Jose E. Tanus-Santos (1)
  
  1. Department of Pharmacology, Faculty of Medicine of Ribeirao Preto, University of Sao Paulo, Av. Bandeirantes, 3900, 14049-900, Ribeirao Preto, SP, Brazil
  2. Department of Psychiatric Nursing and Human Sciences, Ribeirao Preto College of Nursing, University of Sao Paulo, Ribeirao Preto, SP, Brazil
  3. Brazilian Biosciences National Laboratory, CNPEM, Campinas, SP, Brazil
  4. Department of Pharmacy, Faculty of Pharmacy, Federal University of Juiz de Fora, Governador Valadares, MG, Brazil
  5. Santa Casa de Ara?atuba, Ara?atuba, SP, Brazil
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Pharmacology and Toxicology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1041

文摘

Purpose Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that affects blood pressure by promoting vasodilation mediated by nitric oxide. Angiotensin-converting enzyme inhibitors (ACEi) up-regulate the VEGF expression; thus, genetic polymorphisms in the VEGFA gene could affect the antihypertensive responses to these drugs. Methods Hypertensive patients (n--02) were prospectively treated only with the ACEi enalapril for 60?days. We compared the effect of VEGFA polymorphisms on changes in blood pressure after enalapril treatment. In addition, multiple linear regression analysis was carried out to assess the effect of covariates on blood pressure. Genotypes for g.-2578C>A (rs699947), g.-1154G>A (rs1570360), and g.-634G>C (rs2010963) VEGFA polymorphisms were determined, and haplotype frequencies were estimated. Results Individuals carrying the CA and AA genotypes for the g.-2578C>A polymorphism and the AGG haplotype showed more intense decrease in blood pressure in response to enalapril 20?mg/day. A multiple linear regression analysis showed that the AA genotype for the g.-2578C>A polymorphism and the AGG haplotype are associated with more intense decrease in blood pressure in response to enalapril 20?mg/day, while the CC genotype for the g.-2578C>A polymorphism and the CGG haplotype are associated with the opposite effect. Conclusions These findings suggest that polymorphisms in VEGFA gene may affect the antihypertensive responses to enalapril.